Photo: Depositphotos
Jul 18, 2025, 15:32
Vincent Rajkumar: ODAC Votes Against Belantamab Risk-Benefit for Myeloma
Vincent Rajkumar, Professor of Medicine at the Mayo Clinic in Rochester, Minnesota, and Chair for the Mayo Clinic, posted on X:
“Shocker for me.
ODAC votes against belantamab risk benefit for myeloma.
I hope that this vote reflects the way the questions were narrowly worded. I still hope the drug still gets FDA approved.”
Noopur Raje, Oncologist at Mass General Cancer Center, shared this post on X, adding:
“Indeed a shocker!
If a drug going against an anti CD38 antibody head to head in a phase III trial shows a survival benefit, a vote against it makes no sense! Toxicity is manageable with appropriate dose reductions and dose intensity!
Bela has made a real difference to patients!”
More posts featuring Vincent Rajkumar.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jul 18, 2025, 15:32
Jul 18, 2025, 15:32
Jul 18, 2025, 15:11
Jul 18, 2025, 15:05
Jul 18, 2025, 14:54
Jul 18, 2025, 14:33
Jul 18, 2025, 13:54
Jul 18, 2025, 13:34